You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

319 Results
Document
Nov 2022
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    encorafenib - In combination with cetuximab or panitumumab in previously treated BRAF V600E-mutated metastatic colorectal cancer, according to clinical criteria
New Drug Funding Program
    Panitumumab - In Combination with Encorafenib for Previously Treated Metastatic Colorectal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
encorafenib,
PANitumumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2024
Guidelines and Advice
Status: Current
ID: PET 2022-1
Jan 2023
Document
Jan 2023
Document
Jan 2023
Document
Jan 2023
Document
Jan 2023
The High Cost Therapy Funding Program primarily funds high-cost injectable or oral cancer drugs given in inpatient units of the hospital. The...
Document
Apr 2023
Document
Apr 2023
Drug
Other Name(s): Braftovi®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2024
Les fournisseurs de soins primaires sont le premier point de contact pour les femmes, les personnes trans et les personnes non binaires qui peuvent...

Pages